Contract analysis

I. EXECUTIVE SUMMARY Penterra Pharmaceuticals Corp. ("PPC") is challenging $380.4 million in net proposed adjustments across tax years 2017 through 2020, arising from the Internal Revenue Service's challenge to PPC's transfer pricing methodology for its Irish intellectual property holding structure. The adjustments were proposed in a Notice of Proposed Adjustment ("NOPA") issued October 12, 2023, and formalized in a

II. CASE BACKGROUND AND PROCEDURAL HISTORY A. The Parties and Corporate Structure Penterra Pharmaceuticals Corp. ("PPC") is a Delaware corporation listed on the Nasdaq Stock Market under the ticker symbol PPCA. PPC is headquartered at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC is a specialty pharmaceutical and biotechnology company focused on oncology, immunology, and rare disease therapeu

III. SUMMARY OF IRS PROPOSED ADJUSTMENTS The IRS's proposed adjustments, as set forth in the NOPA dated October 12, 2023, total $380.4 million on a net basis across tax years 2017 through 2020. The adjustments are organized into three primary categories, with a correlative offset to avoid double-counting, as summarized below. A. CSA Cost-Sharing Ratio Adjustments ($235.01M) The IRS asserts that PPC's projections of r

IV. KEY ARGUMENTS BY ISSUE This section presents our defense position on each of the five principal issues, organized by the structure of the proposed adjustments. For each issue, we set forth the governing legal framework, the factual basis for our position, the key supporting evidence and analyses, and recommended talking points for the conference. A. CSA Cost-Sharing Ratios — Defense Position

1. Reasonably anticipated benefits (RAB) methodology is sound. PPC's cost-sharing percentages were determined based on projected revenue splits using contemporaneous, well-documented models that are fully consistent with Treas. Reg. § 1.482-7(e). The regulation requires that cost-sharing contributions be proportional to each participant's "reasonably anticipated benefits" from the intangible development activity. PPC

2. Whitmore CPM/TNMM analysis confirms arm's-length results. In addition to the RAB methodology supporting the cost-sharing ratios, Whitmore Valuation Group performed a comparable profits method / transactional net margin method ("CPM/TNMM") analysis that tested PBI's operating margins against a set of 22 comparable distributors and IP-holding companies operating in the pharmaceutical and biotechnology sectors. The c

3. IRS's proposed percentages are inflated and lack empirical support. The IRS's proposed increases of 8 to 12 percentage points to PBI's cost-sharing ratio lack a sound empirical basis. Dr. Washburne's analysis underpinning the proposed adjustments relied on ex post actual revenue data rather than ex ante reasonably anticipated benefits, which fundamentally departs from the regulatory standard. The regulations expli

5. Key talking point. The RAB method used by PPC is the method prescribed by the regulations and was applied consistently from the CSA's inception in 2012 through each of the tax years at issue. The IRS's recharacterization substitutes hindsight for the required prospective analysis. PPC's cost-sharing ratios were based on reasonable, contemporaneous projections, and the resulting profit allocation to PBI is confirme

1. CUT analysis supports 4.5%. Whitmore Valuation Group performed a comprehensive comparable uncontrolled transaction analysis identifying 14 comparable uncontrolled pharmaceutical license agreements. The comparables were identified through a systematic search of publicly available license agreement databases, including Calderon Data Systems, SEC filings, and other industry sources, and were screened for comparabilit

2. IRS's 11.0% rate is unsupported. The IRS's proposed royalty rate of 11.0% is based on a set of purportedly comparable license agreements that are not properly comparable to the PPC/PBI legacy IP license. We have conducted a detailed critique of the IRS's comparable selection and identified the following deficiencies: (a) Several of the IRS's selected CUTs involve early-stage or pre-approval intellectual property,

3. Treas. Reg. § 1.482-4 compliance. PPC's royalty methodology satisfies the comparability requirements under the CUT method as set forth in Treas. Reg. § 1.482-4(c). The regulation requires that a CUT involve substantially the same intangible property under substantially the same circumstances, or that adjustments be made to account for material differences. Whitmore's CUT analysis complies with these requirements b

5. Key talking point. The IRS's proposed 11.0% royalty rate is approximately 2.5 times PPC's 4.5% rate and lies far outside the arm's-length range established by 14 comparable agreements. Even the top of the interquartile range (6.8%) is far below the IRS's proposed 11.0%. The IRS's comparable selection is flawed because it includes agreements that are not properly comparable to the PPC/PBI license — they involve ear

1. Background. Although the PCT payment of $312 million was made on July 1, 2012 — outside the tax years under examination (2017–2020) — the IRS used its view that the PCT was undervalued as a theoretical basis for adjusting the 2017–2020 cost-sharing ratios and royalty rates. The IRS's reasoning, as articulated in the NOPA and Dr. Washburne's analysis, is that an insufficient PCT payment at the inception of the CSA

2. Whitmore DCF analysis. Whitmore Valuation Group performed a discounted cash flow analysis of the pre-existing IP contributed to the CSA, using the income method. The analysis employed a weighted average cost of capital of 9.8%, which reflects the pharmaceutical industry's inherent development and regulatory risk, and yielded a PCT valuation range of $278 million to $361 million. PPC's actual PCT payment of $312 mi

3. IRS's WACC is inappropriate. The single most significant driver of the valuation gap between PPC's position and the IRS's position is the discount rate. The IRS applied a WACC of 7.2%, while PPC's position, supported by Dr. Vasquez's analysis, is that a WACC of 9.8% is appropriate. The IRS's 7.2% discount rate materially understates the risk inherent in pharmaceutical intellectual property commercialization. Dr. V

4. IRS's PCT value of $852 million is aggressive. Using a WACC of 7.2% and overly optimistic revenue projections, the IRS arrived at a PCT value of $852 million — a delta of $540 million over the actual $312 million PCT payment. This figure is driven primarily by the low discount rate, which effectively treats pharmaceutical IP commercialization as having a level of certainty that is unrealistic given the industry's

5. Key talking point. The WACC dispute is the single most significant driver of the valuation gap between PPC's position and the IRS's position. The pharmaceutical industry's inherent development and regulatory risk — including clinical trial failure rates that exceed 90% for early-stage compounds and significant post-approval commercial risks — justifies a meaningfully higher discount rate than the IRS applied. PPC'

1. PBI is a substantive operating entity, not a shell. The IRS's suggestion that PBI lacks economic substance is contradicted by the overwhelming weight of the evidence. By 2020, PBI employed 185 people in Dublin — a more than three-fold increase from the 52 employees it had at its establishment in 2012. PBI occupies approximately 18,000 square feet of office space at its registered office at 4th Floor, Claremont Hou

2. DEMPE functions are performed in Ireland. The IRS's assertion that DEMPE functions remained predominantly in the United States is factually incorrect. PBI performs all five categories of DEMPE functions in Ireland: Development and Enhancement. PBI co-funded research and development costs in amounts ranging from $186 million to $256 million annually during the 2017–2020 period, representing PBI's proportional share

3. Board governance. PBI's board of directors held 42 quarterly and special board meetings in Dublin during the 2017–2020 period. Board minutes, which have been produced in response to IRS IDRs, document substantive decision-making on pricing strategy, market entry and expansion, regulatory strategy, capital expenditures, and other operational matters. The board minutes reflect genuine deliberation and independent ju

4. Employee interviews. During August and September 2022, Calderwood & Harkness conducted interviews of 12 key PBI employees, including the Managing Director, heads of regulatory affairs, commercial operations, medical affairs, supply chain, finance, and legal. These interviews uniformly confirm substantive decision-making authority and operational independence at PBI. The employee interview summaries are included at

5. Independent banking and treasury. PBI maintains an independent banking relationship with Glenmore Bank Ireland plc, through which it manages its own cash flows, treasury operations, and intercompany settlement payments. PBI is not dependent on centralized PPC treasury functions for its day-to-day financial operations.

6. Capital expenditures. PBI has made significant capital expenditures during the 2017–2020 period, investing in regulatory submissions, IT infrastructure (including implementation of an ERP system and pharmacovigilance database), and equipment. These capital expenditures are consistent with PBI's role as a substantive operating entity and demonstrate genuine investment in its non-Americas business.

7. Key talking point. The IRS's economic substance challenge is factually baseless. PBI's headcount of 185 employees, its physical presence at 18,000 square feet of office space in Dublin, its governance structure with 42 board meetings over four years, its regulatory expenditures of €47.2 million, and its independent commercial decision-making across 68 markets demonstrate genuine economic substance that far exceeds

1. Contemporaneous documentation. PPC maintained contemporaneous transfer pricing documentation for all four tax years at issue, prepared by Crestfield & Associates LLP (engagement partner Martin Ogilvy; transfer pricing partner Susan Lam). The documentation was prepared prior to the filing deadline for each tax year's federal income tax return and satisfies the penalty-protection requirements under IRC § 6662(e)(3)(

2. Reasonable cause. PPC reasonably relied on qualified tax professionals — specifically, Crestfield & Associates (a nationally recognized transfer pricing consulting firm) and, for purposes of this examination, Calderwood & Harkness and Whitmore Valuation Group — in determining its transfer pricing positions. PPC applied recognized methodologies that are sanctioned by the Treasury regulations and supported by well-r

3. No gross valuation misstatement. Even if the proposed adjustments were sustained in part, the magnitude of any sustained adjustment would not reach the threshold for the IRC § 6662(h) gross valuation misstatement penalty, which requires that the claimed value be 200% or more (or 50% or less) of the correct value. The IRS itself recognized this by reserving but not asserting the 40% penalty. The absence of a gross

4. Key talking point. PPC's transfer pricing documentation is thorough, timely prepared, and based on sound economic analysis performed by qualified professionals. The documentation satisfies every requirement of Treas. Reg. § 1.6662-6, and PPC's reliance on qualified advisors (Crestfield & Associates) was reasonable. Penalties should be fully abated. The IRS's own decision not to assert the 40% gross valuation misst

V. ANTICIPATED APPEALS OFFICER QUESTIONS AND SUGGESTED RESPONSES The following section sets forth questions that we anticipate Appeals Officer Noreen Castañeda may pose at the conference, along with suggested responses. These questions are based on our review of the NOPA, the examination team's workpapers (to the extent available), our experience with similar Appeals conferences in transfer pricing matters, and the s

VI. OUR SETTLEMENT POSTURE This section is designated for internal use only and must not be shared with or disclosed to the IRS, Appeals Officer Castañeda, or any third party. All team members should be mindful of the privileged nature of this section during the conference. Opening position. The proposed $380.4 million adjustment is unsupported by the facts, the applicable law, and sound economic analysis, and should